Samarth Kulkarni Sells 30,000 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

by · The Markets Daily

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $51.75, for a total transaction of $1,552,500.00. Following the sale, the chief executive officer owned 194,201 shares of the company’s stock, valued at $10,049,901.75. This represents a 13.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

  • On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Stock Up 10.8%

Shares of CRISPR Therapeutics stock traded up $5.93 during trading on Thursday, reaching $60.66. 3,423,606 shares of the stock were exchanged, compared to its average volume of 1,904,723. The firm has a market cap of $5.78 billion, a price-to-earnings ratio of -10.85 and a beta of 1.70. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The stock’s fifty day moving average is $54.88 and its 200 day moving average is $58.35.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.15. The business had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. Equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Institutional Trading of CRISPR Therapeutics

Several large investors have recently modified their holdings of CRSP. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of CRISPR Therapeutics by 5.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after purchasing an additional 180 shares during the period. IFP Advisors Inc lifted its position in CRISPR Therapeutics by 24.6% during the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after purchasing an additional 181 shares in the last quarter. Cerity Partners LLC increased its position in CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock worth $318,000 after buying an additional 190 shares in the last quarter. Peapack Gladstone Financial Corp boosted its position in shares of CRISPR Therapeutics by 3.0% in the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after purchasing an additional 200 shares during the period. Finally, Optiver Holding B.V. increased its stake in shares of CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after purchasing an additional 210 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the subject of several recent research reports. Citigroup reissued a “buy” rating and set a $77.00 price objective (down previously from $87.00) on shares of CRISPR Therapeutics in a research report on Tuesday, November 11th. Royal Bank Of Canada raised their target price on shares of CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 11th. Needham & Company LLC restated a “buy” rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 23rd. Citizens Jmp reissued a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 23rd. Finally, Robert W. Baird cut their target price on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Twelve analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $68.35.

View Our Latest Stock Analysis on CRISPR Therapeutics

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

See Also